As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of mogamulizumab for previously treated cutaneous T-cell lymphoma (mycosis fungoides or Sézary syndrome). Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during early October 2019 when we will write to you about how you can get involved.